Last reviewed · How we verify
NCT04276610: WOTB
Words on the Brain: Can Reading Rehabilitation for Age-Related Vision Impairment Improve Cognitive Functioning?
NA trial testing Low Vision Reading Rehabilitation in Age-related Macular Degeneration in 38 participants. Terminated before completion.
28 March 2023
Quick facts
| Lead sponsor | Université de Montréal |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 16 May 2017 |
| Primary completion | 28 March 2023 |
| Estimated completion | 28 March 2023 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Low Vision Reading Rehabilitation
Conditions studied
- Age-related Macular Degeneration — all drugs for Age-related Macular Degeneration →
- Dementia — all drugs for Dementia →
- Low Vision — all drugs for Low Vision →
- Low Vision Aids — all drugs for Low Vision Aids →
Sponsor
Université de Montréal — full company profile →
Who can join
65 and older, any sex, with Age-related Macular Degeneration or Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Age-related vision impairment and dementia both become more prevalent with increasing age. Research into the mechanisms of these conditions has proposed that some of their causes (e.g., macular degeneration/glaucoma and Alzheimer's disease) could be symptoms of an underlying common cause, or may be equally linked to a multifactorial context in frailty and aging. Research into sensory-cognitive aging has provided preliminary data that sensory decline may be linked to the progression of dementia through the concept of sensory deprivation. Preliminary data in hearing loss rehabilitation support the idea that improved hearing may have a beneficial effect on cognitive functioning; however, there are to date no data available to examine whether low vision rehabilitation, specifically for reading, could have an equally protective or beneficial effect on cognitive health. The present proposal aims to fill this gap.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04276610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06961370 — A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693 · Phase 1 · recruiting
- NCT06458595 — Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) · Phase 1, PHASE2 · recruiting
- NCT03848663 — Visual Remapping to Aid Reading With Field Loss · NA · recruiting
- NCT04735263 — Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD · Phase 2 · recruiting
- NCT03752840 — Village-Integrated Eye Worker Trial II · NA · recruiting
Other Université de Montréal trials
Trials by the same sponsor.
- NCT07389837 — Maple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance · NA · not yet recruiting
- NCT07259382 — Neuro-Inflammation in Extremity Trauma: Risk Verification in Elbow Trauma: The NERVE Study · not yet recruiting
- NCT07194629 — Pilot and Feasibility Study of Impact of SDF 38% Application on Oral Health of Elderly With Autonomy Loss · Phase 4 · not yet recruiting
- NCT06527274 — Effect of Defocus in Soft Contact Lenses on Internal Retinal Vascularization · NA · active not recruiting
- NCT06634264 — Comparison of Two Reeducation Methods in Children With Persistent Sleep Apnea, a Randomized Controlled Trial · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04276610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Montréal
- Last refreshed: 3 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04276610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing